Tenofovir-induced fanconi syndrome in a patient with chronic hepatitis B monoinfection

Annals of Hepatology

Volumn 15, Issue 2, 2016, Pages 273-276

  Conti, Fabio ^a   Vitale, Giovanni ^a   Cursaro, Carmela ^a   Bernardi, Mauro ^a   Andreone, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatitis B virus; Nephropathy; Renal toxicity

Indexed keywords

25 HYDROXYVITAMIN D; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BICARBONATE; CALCIUM; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PARATHYROID HORMONE; PHOSPHATASE; PHOSPHATE; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; TENOFOVIR;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BONE PAIN; CASE REPORT; CHRONIC HEPATITIS B; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; MUSCLE WEAKNESS; PHOSPHATE BLOOD LEVEL; PROTEINURIA; RENAL DIABETES; RISK FACTOR; TREATMENT FAILURE; URINALYSIS; VIRUS REPLICATION; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CONVALESCENCE; DEPRESCRIPTION; HEPATITIS B, CHRONIC;

ANTIVIRAL AGENTS; DEPRESCRIPTIONS; FANCONI SYNDROME; GLOMERULAR FILTRATION RATE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; TENOFOVIR;

EID: 84957077835     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.5604/16652681.1193725     Document Type: Article

References (14)

1. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377-86
2. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75
3. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2014 [Epub ahead of print]
4. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, et al. The safety of tenofovir disoproxil- fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 1273-81
5. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxilfumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505
6. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80
7. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi’s syndrome. Am J Kidney Dis 2003; 41: 292-309
8. Samarkos M, Theofanis V, Eliadi I, Vlachogiannakos J, Polyzos A. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B. J Gastrointestin Liver Dis 2014;23(3):342
9. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir- associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013; 18: 945-48
10. Viganò M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F, Fugazza A, et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol 2014; 61(4): 600-3
11. Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology 2015 [Epub ahead of print].
12. European Association For the Study of The Liver (EASL) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85
13. Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42 (10): 1488-95
14. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49(5): 1503-14.